×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LXRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/23
03:53 am
lxrx
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data [Yahoo! Finance]
4/17
08:00 am
lxrx
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Low
Report
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
3/24
08:00 am
lxrx
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Medium
Report
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
3/23
11:25 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
3/23
07:40 am
lxrx
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]
3/23
07:30 am
lxrx
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Medium
Report
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
3/20
06:20 pm
lxrx
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Medium
Report
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
3/12
03:09 pm
lxrx
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Low
Report
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Date
Time
Symbol
Company Name
Action
%Chg
3/5/2026
06:59 am
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
4.5%
lexicon pharmaceuticals, inc.
11/6/2025
07:30 am
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
4.4%
lexicon pharmaceuticals, inc.
8/6/2025
07:30 am
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
8.5%
lexicon pharmaceuticals, inc.
5/13/2025
04:00 pm
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
-15.6%
lexicon pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
3/16
04:06 pm
lxrx
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31
Low
Report
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31
3/16
04:04 pm
lxrx
Form DEFA14A LEXICON PHARMACEUTICALS,
Low
Report
Form DEFA14A LEXICON PHARMACEUTICALS,
3/16
04:03 pm
lxrx
Form DEF 14A LEXICON PHARMACEUTICALS, For: Mar 16
Neutral
Report
Form DEF 14A LEXICON PHARMACEUTICALS, For: Mar 16
3/5
04:51 pm
lxrx
Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31
Medium
Report
Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31
3/5
07:02 am
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Mar 05
Medium
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Mar 05
3/3
07:21 am
lxrx
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: McDermott Wendy
Medium
Report
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: McDermott Wendy
3/3
07:20 am
lxrx
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Martens Rachel Yap
Medium
Report
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Martens Rachel Yap
3/3
07:19 am
lxrx
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Granowitz Craig B
Medium
Report
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Granowitz Craig B
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug [MarketWatch]
58.0%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
TOP News Decliners
7/26
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
-43.7%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: